scholarly journals Parkinson’s Disease Patients with Dopamine Dysregulation Syndrome-Editorial Review

2020 ◽  
Vol 4 (9) ◽  
pp. 90-96
Author(s):  
Hristina Popovska ◽  
Igor Petrov
2016 ◽  
Vol 28 ◽  
pp. 152-154 ◽  
Author(s):  
Lucia Ricciardi ◽  
Kristy J. Espay ◽  
Robert Krikorian ◽  
Alfonso Fasano ◽  
Alberto J. Espay

2020 ◽  
Vol 26 (6) ◽  
pp. 333-342 ◽  
Author(s):  
Shoned Jones ◽  
Kelli M. Torsney ◽  
Lily Scourfield ◽  
Katie Berryman ◽  
Emily J. Henderson

SUMMARYHistorically, Parkinson's disease was viewed as a motor disorder and it is only in recent years that the spectrum of non-motor disorders associated with the condition has been fully recognised. There is a broad scope of neuropsychiatric manifestations, including depression, anxiety, apathy, psychosis and cognitive impairment. Patients are more predisposed to delirium, and Parkinson's disease treatments give rise to specific syndromes, including impulse control disorders, dopamine agonist withdrawal syndrome and dopamine dysregulation syndrome. This article gives a broad overview of the spectrum of these conditions, describes the association with severity of Parkinson's disease and the degree to which dopaminergic degeneration and/or treatment influence symptoms. We highlight useful assessment scales that inform diagnosis and current treatment strategies to ameliorate these troublesome symptoms, which frequently negatively affect quality of life.


Author(s):  
S Sasikumar ◽  
R Matta ◽  
A Fasano

Background: Dopamine Dysregulation Syndrome (DDS) is an adverse non-motor complication of dopamine replacement therapy in Parkinson’s Disease. The current literature on DDS is limited, and it remains underdiagnosed and challenging to manage. Methods: We performed a retrospective chart review and classified patients according to risk factors that have been identified in the literature, UPDRS scores, intervention and outcome. Univariate analyses were performed to quantify these characteristics. Results: Prior psychiatric illness was identified in 70% of patients, impulse control disorder in 89% and substance abuse in 3.7%. Interventions included reduction of dopamine therapy (88.9%), deep brain stimulation (DBS) of the subthalamic nucleus (STN, 48.1%) or globus pallidus interna (GPi, 7.4%), and levodopa-carbidopa intestinal gel (LCIG) infusion (11.1%). Baseline UPDRS IV before treatment and MDS III after treatment were not significant between intervention groups (p=0.09 and p=0.13 respectively). Overall 88.9% patients improved at follow up, with medication only (75%), STN DBS (100%), GPi DBS (100%) and LCIG (33%). Relapse rate was 18.2%, in the STN group only. Conclusions: Our results suggest that GPi DBS, in concurrence with dopaminergic medication reduction, is the most effective intervention. STN DBS might be also beneficial although the associated medications reduction causes DDS relapse in a subgroup of patients.


2014 ◽  
Vol 4 (1) ◽  
pp. 37-41
Author(s):  
Abdulraheem M. Alshehri

Parkinson's disease is a common neurodegenerative disease, with a worldwide incidence of about 10-20 in 100,000. Its diagnosis remains clinical, and it requires bradykinesia plus one of the following: Rest tremor, rigidity or postural instability. Dopaminergic therapy including levodopa and dopamine agonists has allowed a reasonable control over the motor symptoms, but it offered no help for the non-motor manifestations. To the contrary, dopaminergic antiparkinson therapy was the most likely culprit in the emergence of a new set of impulse control disorders including:  Pathological gambling, hypersexuality, compulsive shopping, compulsive eating, punding (complex, repetitive, excessive, non-goal oriented behaviors), walkabout, and dopamine dysregulation syndrome. A case series of three main impulse control disorders in Parkinson's disease is presented here with a review of the current thinking regarding diagnosis and treatment.


Sign in / Sign up

Export Citation Format

Share Document